---
title: "Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Clinical evidence"
description: "Formulary evidence on Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Clinical evidence. Covers HOPE-3, HOPE-2, HOPE-2-OLE, HOPE-OLE, and HOPE-Duchenne. 115 evidence topics quoted from 32 sources."
canonical: "https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 HOPE-3

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Efficacy and safety objective

> “evaluating the efficacy and safety of a cell therapy called deramiocel”

Source: [University of California, Davis (2026)](https://clinicaltrials.ucdavis.edu/trial/NCT05126758)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### United States trial sites

> “20 trial sites in USA”

Source: [Capricor Therapeutics AAN presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_98d9213fd51a80017b9973bdbafc2d14/capricor/files/631961/CAPR_AAN_%282026_Presentation%29.pdf)

<a id="topic-3.1.1.2-2"></a>

###### Enrollment period

| Milestone | Reported date |
| --- | --- |
| Enrollment began | “June 22, 2022” |
| Enrollment ended | “May 28, 2024” |

Source: [McDonald et al. (2026)](https://d1io3yog0oux5.cloudfront.net/_fe6d5f8f9bad70880b7ed653911dd676/capricor/files/Lancet_%28HOPE-3%29_Phase_3_publication.pdf)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Randomization, masking, and comparator

> “Randomized (1:1), double-blind, placebo-controlled study”

Source: [Capricor Therapeutics AAN presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_98d9213fd51a80017b9973bdbafc2d14/capricor/files/631961/CAPR_AAN_%282026_Presentation%29.pdf)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Age, ambulation, and cardiac eligibility

> “Ages ≥ 10 who are late or non-ambulatory”
> “LVEF ≥ 35%”

Source: [Capricor Therapeutics AAN presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_98d9213fd51a80017b9973bdbafc2d14/capricor/files/631961/CAPR_AAN_%282026_Presentation%29.pdf)

<a id="topic-3.1.1.4-2"></a>

###### Upper-limb impairment criterion

> “total PUL score less than or equal to 40”

Source: [University of California, Davis (2026)](https://clinicaltrials.ucdavis.edu/trial/NCT05126758)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Investigational dose, route, and treatment duration

> “Participants received intravenous Deramiocel at 150 million cells per infusion or placebo every three months for a 12-month period.”

Source: [Capricor Therapeutics HOPE-3 topline results announcement (2025)](https://www.capricor.com/investors/news-events/press-releases/detail/331/capricor-therapeutics-announces-positive-topline-results)

<a id="topic-3.1.1.5-2"></a>

###### Background corticosteroid therapy

> “All patients on background stable corticosteroid therapy”

Source: [Capricor Therapeutics AAN presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_98d9213fd51a80017b9973bdbafc2d14/capricor/files/631961/CAPR_AAN_%282026_Presentation%29.pdf)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Performance of the Upper Limb 2.0 Total Score as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary upper-limb instrument

> “Performance of Upper Limb (PUL v2.0)”

Source: [Capricor Therapeutics AAN presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_98d9213fd51a80017b9973bdbafc2d14/capricor/files/631961/CAPR_AAN_%282026_Presentation%29.pdf)

<a id="topic-3.1.1.6.1-2"></a>

###### Outcome-instrument validation: PUL versions 1.2 and 2.0

> “Our results confirm that the PUL 1.2 and 2.0 versions detect change in all domains over 2 years.”

Source: [Mayhew et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31538331/)

<a id="topic-3.1.1.6.1-3"></a>

###### Outcome-instrument validation: patient perspectives on meaningful change in NSAA and PUL

> “items that are meaningful differ based on ability level”
> “maintaining function in lower and upper limbs is the ultimate goal”

Source: [Gillman et al. (2025)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1509174/full)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Sample-size assumptions in the publication

| Assumption | Reported value |
| --- | --- |
| Planned participants per treatment group | “49” |
| Statistical power | “90%” |

Source: [McDonald et al. (2026)](https://d1io3yog0oux5.cloudfront.net/_fe6d5f8f9bad70880b7ed653911dd676/capricor/files/Lancet_%28HOPE-3%29_Phase_3_publication.pdf)

<a id="topic-3.1.1.7.1-2"></a>

###### Randomized participants

| Population | Participants |
| --- | --- |
| Total randomized | “106” |
| Allocated to deramiocel | “54” |
| Allocated to placebo | “52” |

Source: [Capricor Therapeutics AAN presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_98d9213fd51a80017b9973bdbafc2d14/capricor/files/631961/CAPR_AAN_%282026_Presentation%29.pdf)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Published analysis population

> “intention-to-treat (ITT) population”

Source: [McDonald et al. (2026)](https://d1io3yog0oux5.cloudfront.net/_fe6d5f8f9bad70880b7ed653911dd676/capricor/files/Lancet_%28HOPE-3%29_Phase_3_publication.pdf)

<a id="topic-3.1.1.7.2-2"></a>

###### Sponsor-described primary analysis

> “prespecified repeated measures model using percent change from BL”

Source: [Capricor Therapeutics AAN presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_98d9213fd51a80017b9973bdbafc2d14/capricor/files/631961/CAPR_AAN_%282026_Presentation%29.pdf)

<a id="topic-3.1.1.7.2-3"></a>

###### Primary analysis populations compared by FDA

| Analysis | Participants |
| --- | --- |
| Prespecified SAP 1.1 | “104” |
| Post-study modified SAP 3.0 | “105” |

Source: [FDA presentation (2026)](https://www.fda.gov/media/193912/download)

<a id="topic-3.1.1.7.2-4"></a>

###### FDA assessment of statistical changes

> “BLA submission included additional statistical changes without an associated, updated SAP.”

Source: [FDA briefing document (2026)](https://www.fda.gov/media/193839/download)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Treatment non-initiation and discontinuations

| Disposition | Participants |
| --- | --- |
| Deramiocel: did not receive treatment | “1” |
| Deramiocel: withdrew consent | “3” |
| Placebo: withdrew consent | “1” |
| Placebo: discontinuation due to an adverse event | “1” |

Source: [Capricor Therapeutics MDA presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_72a8420b8089fb55954d5909808b3da2/capricor/files/631961/MDA_2026_CAPR_3.11.26_late-breaker.pdf)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### HOPE-3: baseline demographics

| “Baseline Demographics”            | “Overall (n=106)” |
| ---------------------------------- | ----------------: |
| “Age (years)” / “Mean (SD)”        |     “15.0 (3.04)” |
| “Min, Max”                         |          “10, 22” |
| “Non-ambulatory”                   |       “90 (84.9)” |
| “Diagnosed cardiomyopathy” / “Yes” |       “79 (74.5)” |

Source: [Capricor Therapeutics MDA presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_72a8420b8089fb55954d5909808b3da2/capricor/files/631961/MDA_2026_CAPR_3.11.26_late-breaker.pdf)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Published total PUL2.0 result: between-group difference in mean percentage change at month 12

> “4·55% (95% CI 0·47–8·63; p=0·029)”

Source: [McDonald et al. (2026)](https://d1io3yog0oux5.cloudfront.net/_fe6d5f8f9bad70880b7ed653911dd676/capricor/files/Lancet_%28HOPE-3%29_Phase_3_publication.pdf)

<a id="topic-3.1.1.8.3-2"></a>

###### HOPE-3: cardiac endpoint in the published trial

> “The key secondary endpoint of left ventricular ejection fraction (LVEF) did not reach statistical significance, although the difference favoured deramiocel.”
> “p=0·0935”

Source: [McDonald et al. (2026)](https://d1io3yog0oux5.cloudfront.net/_fe6d5f8f9bad70880b7ed653911dd676/capricor/files/Lancet_%28HOPE-3%29_Phase_3_publication.pdf)

<a id="topic-3.1.1.8.3-3"></a>

###### HOPE-3: FDA assessment of prespecified analyses

> “The study did not meet its pre-specified primary and secondary efficacy endpoints”

Source: [FDA briefing document (2026)](https://www.fda.gov/media/193839/download)

<a id="topic-3.1.1.8.3-4"></a>

###### FDA analysis using the prespecified statistical analysis plan

| Endpoint | Deramiocel minus placebo | Nominal p value |
| --- | --- | --- |
| PUL 2.0 total score: absolute change | “0.66” | “0.24” |
| LVEF: change in percentage points | “-0.04%” | “0.97” |

Source: [FDA presentation (2026)](https://www.fda.gov/media/193912/download)

Additional sources: [Iannaccone et al. (2026)](https://www.neurology.org/doi/10.1212/WNL.0000000000217921)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### Patient Global Impression of Severity: FDA mean difference and 95% confidence interval

> “-0.25 (-0.60, 0.09)”

Source: [FDA presentation (2026)](https://www.fda.gov/media/193912/download)

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### HOPE-3: safety table notation

> “n (%), e”

Source: [FDA presentation (2026)](https://www.fda.gov/media/193912/download)

<a id="topic-3.1.1.8.5-2"></a>

###### HOPE-3: headache and hypersensitivity reactions

| “Event”                      | “Deramiocel (N=53)” | “Placebo (N=52)” |
| ---------------------------- | ------------------: | ---------------: |
| “Headache”                   |     “32 (60.4), 91” |     “2 (3.8), 2” |
| “Hypersensitivity Reactions” |     “22 (41.5), 55” |   “8 (15.4), 18” |

Source: [FDA presentation (2026)](https://www.fda.gov/media/193912/download)

<a id="topic-3.1.1.8.5-3"></a>

###### Mortality during the controlled study

> “No deaths occurred in the study.”

Source: [McDonald et al. (2026)](https://d1io3yog0oux5.cloudfront.net/_fe6d5f8f9bad70880b7ed653911dd676/capricor/files/Lancet_%28HOPE-3%29_Phase_3_publication.pdf)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

HOPE-3 randomized 106 participants, of whom 90 (84.9%) were non-ambulatory. The published percentage-change analysis favoured deramiocel, whereas FDA’s analysis using the prespecified plan did not demonstrate a significant difference in the primary endpoint. FDA also identified statistical changes without an updated SAP. The published key secondary LVEF result was not statistically significant. These findings require the analysis scale, analysis population, and statistical plan to remain distinguishable. The Patient Global Impression of Severity confidence interval included no difference. The 12-month controlled comparison and its predominantly non-ambulatory population do not establish effects on long-term survival or applicability across all DMD stages.

Source: [McDonald et al. (2026)](https://d1io3yog0oux5.cloudfront.net/_fe6d5f8f9bad70880b7ed653911dd676/capricor/files/Lancet_%28HOPE-3%29_Phase_3_publication.pdf); [Capricor Therapeutics MDA presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_72a8420b8089fb55954d5909808b3da2/capricor/files/631961/MDA_2026_CAPR_3.11.26_late-breaker.pdf); [FDA briefing document (2026)](https://www.fda.gov/media/193839/download); [FDA presentation (2026)](https://www.fda.gov/media/193912/download)

<a id="heading-3.1.2"></a>

#### 3.1.2 HOPE-2

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Safety and efficacy of repeat treatment

> “the safety and efficacy of repeat doses of CAP-1002”

Source: [Capricor Therapeutics fourth quarter 2018 results announcement (2019)](https://www.capricor.com/investors/news-events/press-releases/detail/88/capricor-therapeutics-reports-fourth-quarter-and-full-year)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### United States study centers

> “seven centres in the USA”

Source: [McDonald et al. (2022)](https://d1io3yog0oux5.cloudfront.net/capricor/files/pages/our-science/publications/Lancet-Paper-CAP1002.pdf)

<a id="topic-3.1.2.2-2"></a>

###### Study period reported in the publication

| Milestone | Reported date |
| --- | --- |
| Beginning of reported study period | “March 1, 2018” |
| End of reported study period | “March 31, 2020” |

Source: [McDonald et al. (2022)](https://d1io3yog0oux5.cloudfront.net/capricor/files/pages/our-science/publications/Lancet-Paper-CAP1002.pdf)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Randomized phase 2 design

> “Phase II, randomized, double-blind, placebo-controlled study”

Source: [Capricor Therapeutics fourth quarter 2018 results announcement (2019)](https://www.capricor.com/investors/news-events/press-releases/detail/88/capricor-therapeutics-reports-fourth-quarter-and-full-year)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Age and sex criterion

> “Male subjects at least 10 years of age”

Source: [Capricor Therapeutics HOPE-2 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/80/NCT03406780/Prot_001.pdf)

<a id="topic-3.1.2.4-2"></a>

###### PUL entry criterion

> “entry item score 2-5”

Source: [Capricor Therapeutics HOPE-2 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/80/NCT03406780/Prot_001.pdf)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Intravenous regimen in the amended protocol

> “150 million CDCs”
> “once every 3 months”
> “total of 4 administrations”

Source: [Capricor Therapeutics HOPE-2 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/80/NCT03406780/Prot_001.pdf)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Performance of the Upper Limb 1.2 Mid-level Elbow Score as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary upper-limb domain

> “mid-level (elbow) dimension of the PUL 1.2”

Source: [Capricor Therapeutics HOPE-2 statistical analysis plan (2020)](https://cdn.clinicaltrials.gov/large-docs/80/NCT03406780/SAP_002.pdf)

<a id="topic-3.1.2.6.1-2"></a>

###### Outcome-instrument validation: PUL development

> “The involvement of patients and families helped to select items reflecting clinically meaningful activities of daily living.”

Source: [Mayhew et al. (2013)](https://onlinelibrary.wiley.com/doi/10.1111/dmcn.12213)

<a id="topic-3.1.2.6.1-3"></a>

###### Outcome-instrument reliability

> “PUL module reliability on people diagnosed with DMD, BMD, and LGMD”
> “ICC(2, 1) resulted in being equal to 0.9943”

Source: [Gandolla et al. (2020)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0239064)

Additional sources: [Pane et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24440357/)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Original target and FDA efficacy analysis population

| Population | Participants |
| --- | --- |
| Original planned enrollment | “84” |
| FDA repeated-measures primary analysis | “19” |

Source: [FDA presentation (2026)](https://www.fda.gov/media/193912/download)

<a id="topic-3.1.2.7.1-2"></a>

###### Amended protocol enrollment limit

> “20”

Source: [Capricor Therapeutics HOPE-2 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/80/NCT03406780/Prot_001.pdf)

<a id="topic-3.1.2.7.1-3"></a>

###### Actual randomized allocation

| Population | Participants |
| --- | --- |
| Randomized | “20” |
| CAP-1002 | “8” |
| Placebo | “12” |

Source: [McDonald et al. (2023)](https://d1io3yog0oux5.cloudfront.net/_e7a3fba205f4fce31284150e8f43c824/capricor/files/Long_Term_Safety_and_Efficacy_of_CAP-1002_in_late-stage_patients_with_DMD_Poster.pdf)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Analysis-set definitions

| Analysis set | Definition excerpt |
| --- | --- |
| Intention to treat | “all subjects who are randomized” |
| Safety | “all subjects who receive IP” |

Source: [Capricor Therapeutics HOPE-2 statistical analysis plan (2020)](https://cdn.clinicaltrials.gov/large-docs/80/NCT03406780/SAP_002.pdf)

<a id="topic-3.1.2.7.2-2"></a>

###### Repeated-measures method

> “mixed-model repeated measures (MMRM)”

Source: [Capricor Therapeutics HOPE-2 statistical analysis plan (2020)](https://cdn.clinicaltrials.gov/large-docs/80/NCT03406780/SAP_002.pdf)

<a id="topic-3.1.2.7.2-3"></a>

###### Primary efficacy endpoint: missing-data handling

> “no imputation”

Source: [Capricor Therapeutics HOPE-2 statistical analysis plan (2020)](https://cdn.clinicaltrials.gov/large-docs/80/NCT03406780/SAP_002.pdf)

<a id="topic-3.1.2.7.2-4"></a>

###### Subsequent efficacy p values

> “considered nominal”

Source: [Capricor Therapeutics HOPE-2 statistical analysis plan (2020)](https://cdn.clinicaltrials.gov/large-docs/80/NCT03406780/SAP_002.pdf)

<a id="topic-3.1.2.7.2-5"></a>

###### FDA assessment of post-unblinding changes

> “After data unblinding, Applicant modified the statistical analysis plan”

Source: [FDA presentation (2026)](https://www.fda.gov/media/193912/download)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Screening and 12-month disposition

| Disposition | Participants |
| --- | --- |
| Screened | “26” |
| Screen failures | “6” |
| CAP-1002 completers | “7” |
| Placebo completers | “9” |

Source: [McDonald et al. (2023)](https://d1io3yog0oux5.cloudfront.net/_e7a3fba205f4fce31284150e8f43c824/capricor/files/Long_Term_Safety_and_Efficacy_of_CAP-1002_in_late-stage_patients_with_DMD_Poster.pdf)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Age and ambulation at baseline

| Characteristic | CAP-1002, 8 participants | Placebo, 12 participants |
| --- | --- | --- |
| Age in years, mean and standard deviation | “14 (3·2)” | “14 (2·9)” |
| Non-ambulatory, number and percentage | “7 (88%)” | “11 (92%)” |

Source: [McDonald et al. (2022)](https://d1io3yog0oux5.cloudfront.net/capricor/files/pages/our-science/publications/Lancet-Paper-CAP1002.pdf)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### HOPE-2: upper-limb endpoint

> “mid-level elbow PUL1.2 favoured CAP-1002 over placebo (percentile difference 36·2, 95% CI 12·7–59·7; difference of 2·6 points; p=0·014).”

Source: [McDonald et al. (2022)](https://d1io3yog0oux5.cloudfront.net/capricor/files/pages/our-science/publications/Lancet-Paper-CAP1002.pdf)

<a id="topic-3.1.2.8.3-2"></a>

###### Confidence interval for the percentile difference in the full-text results

> “7·9–64·5”

Source: [McDonald et al. (2022)](https://d1io3yog0oux5.cloudfront.net/capricor/files/pages/our-science/publications/Lancet-Paper-CAP1002.pdf)

<a id="topic-3.1.2.8.3-3"></a>

###### FDA analysis of the primary endpoint on the original scale

| Measure | Reported result |
| --- | --- |
| Between-group difference in change at month 12 | “2.98” |
| 95% confidence interval | “-0.95 – 6.91” |
| Nominal p value | “0.13” |

Source: [FDA presentation (2026)](https://www.fda.gov/media/193912/download)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Published infusion-related hypersensitivity findings

| Finding | Reported participants |
| --- | --- |
| Infusion-related hypersensitivity reactions | “three patients” |
| Treatment discontinuation because of a severe allergic reaction | “one patient” |

Source: [McDonald et al. (2022)](https://d1io3yog0oux5.cloudfront.net/capricor/files/pages/our-science/publications/Lancet-Paper-CAP1002.pdf)

<a id="topic-3.1.2.8.5-2"></a>

###### HOPE-2: historical safety event and premedication

> “a patient had a serious adverse event in the form of anaphylaxis.”
> “we initiated a pre-medication strategy”

Source: [Capricor Therapeutics fourth quarter 2018 results announcement (2019)](https://www.capricor.com/investors/news-events/press-releases/detail/88/capricor-therapeutics-reports-fourth-quarter-and-full-year)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

HOPE-2 enrolled 20 participants rather than the original target of 84; an amended protocol limited enrollment to 20. Allocation was 8 to CAP-1002 and 12 to placebo, and the FDA primary efficacy analysis included 19 participants. The publication reported a significant percentile-rank result, whereas FDA’s original-scale analysis had a confidence interval crossing zero and a nominal p value of 0.13. FDA identified changes to the statistical plan after unblinding. The SAP described subsequent efficacy p values as nominal. The abstract and full-text results report different confidence intervals for the percentile difference. The small sample, incomplete follow-up, and disagreement between analyses limit precision and confidence in the treatment-effect estimate.

Source: [FDA presentation (2026)](https://www.fda.gov/media/193912/download); [McDonald et al. (2022)](https://d1io3yog0oux5.cloudfront.net/capricor/files/pages/our-science/publications/Lancet-Paper-CAP1002.pdf); [McDonald et al. (2023)](https://d1io3yog0oux5.cloudfront.net/_e7a3fba205f4fce31284150e8f43c824/capricor/files/Long_Term_Safety_and_Efficacy_of_CAP-1002_in_late-stage_patients_with_DMD_Poster.pdf); [Capricor Therapeutics HOPE-2 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/80/NCT03406780/Prot_001.pdf); [Capricor Therapeutics HOPE-2 statistical analysis plan (2020)](https://cdn.clinicaltrials.gov/large-docs/80/NCT03406780/SAP_002.pdf)

<a id="topic-3.1.2.9-2"></a>

###### Historical constraint on further enrollment

> “will not commence until additional funding is secured.”

Source: [Capricor Therapeutics fourth quarter 2018 results announcement (2019)](https://www.capricor.com/investors/news-events/press-releases/detail/88/capricor-therapeutics-reports-fourth-quarter-and-full-year)

Additional sources: [Lempriere (2022)](https://pubmed.ncbi.nlm.nih.gov/35396359/)

<a id="heading-3.1.3"></a>

#### 3.1.3 HOPE-2-OLE

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Safety and efficacy objective

> “assess the safety and efficacy”

Source: [Capricor Therapeutics HOPE-2-OLE statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/76/NCT04428476/SAP_001.pdf)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Study initiation and country

| Item | Reported value |
| --- | --- |
| Study start | “August 2020” |
| Country | “United States” |

Source: [University of California, Davis (2025)](https://clinicaltrials.ucdavis.edu/trial/NCT04428476)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Open-label extension design

> “Phase 2, multi-center, open-label extension trial”

Source: [University of California, Davis (2025)](https://clinicaltrials.ucdavis.edu/trial/NCT04428476)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Prior HOPE-2 participation

> “Documented enrollment in the HOPE-2 trial and completion of trial follow-up through Month 12”

Source: [University of California, Davis (2025)](https://clinicaltrials.ucdavis.edu/trial/NCT04428476)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Extension dosing

> “150M cells IV every 3 months”

Source: [Capricor Therapeutics PPMD presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_44a0a21427a90b1030ae38c70ae1faf7/capricor/files/PPMD_2026_HOPE-2_OLE_Late-breaker_6.27.26.pdf)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Performance of the Upper Limb 2.0 Combined Total Score as the Primary Efficacy Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary efficacy measure and assessment time

> “PUL 2.0 Combined Total Score”
> “12-month timepoint”

Source: [Capricor Therapeutics HOPE-2-OLE statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/76/NCT04428476/SAP_001.pdf)

<a id="topic-3.1.3.6.1-2"></a>

###### Outcome-instrument validation: PUL 24-month natural history

> “over 24 months non-ambulant patients showed a bigger decrease in total scores compared to the ambulant ones (4.36 vs 2.07 points).”

Source: [Pane et al. (2018)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0199223)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### HOPE-2 open-label extension: enrollment

> “13 enrolled in HOPE-2-OLE”

Source: [Capricor Therapeutics PPMD presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_44a0a21427a90b1030ae38c70ae1faf7/capricor/files/PPMD_2026_HOPE-2_OLE_Late-breaker_6.27.26.pdf)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Safety and enrolled analysis populations

> “all 13 subjects analyzed”

Source: [Capricor Therapeutics PPMD presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_44a0a21427a90b1030ae38c70ae1faf7/capricor/files/PPMD_2026_HOPE-2_OLE_Late-breaker_6.27.26.pdf)

<a id="topic-3.1.3.7.2-2"></a>

###### Combined parent-trial and extension model

> “The linear mixed model uses all available data for all 20 subjects (12 completers).”

Source: [McDonald et al. (2023)](https://d1io3yog0oux5.cloudfront.net/_e7a3fba205f4fce31284150e8f43c824/capricor/files/Long_Term_Safety_and_Efficacy_of_CAP-1002_in_late-stage_patients_with_DMD_Poster.pdf)

<a id="topic-3.1.3.7.2-3"></a>

###### HOPE-2 and open-label extension: 24-month analysis and off-treatment comparison methodology

> “2nd 12 months was calculated using a linear interpolation, since the off-treatment phase length varied by subject.”

Source: [McDonald et al. (2023)](https://d1io3yog0oux5.cloudfront.net/_e7a3fba205f4fce31284150e8f43c824/capricor/files/Long_Term_Safety_and_Efficacy_of_CAP-1002_in_late-stage_patients_with_DMD_Poster.pdf)

<a id="topic-3.1.3.7.2-4"></a>

###### Multiplicity

> “There will be no adjustment for multiplicity of analyses.”

Source: [Capricor Therapeutics HOPE-2-OLE statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/76/NCT04428476/SAP_001.pdf)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### HOPE-2 open-label extension: treatment and five-year disposition

> “All received deramiocel”
> “9 continued to Month 60”

Source: [Capricor Therapeutics PPMD presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_44a0a21427a90b1030ae38c70ae1faf7/capricor/files/PPMD_2026_HOPE-2_OLE_Late-breaker_6.27.26.pdf)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Extension baseline characteristics

| Characteristic | Reported value |
| --- | --- |
| Sex and ambulation | “all non-ambulant males” |
| Mean age | “16.5 yr” |
| Age range, years | “12–23” |
| Mean PUL 2.0 total score | “20.4” |
| Mean LVEF, percent | “51.2” |

Source: [Capricor Therapeutics PPMD presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_44a0a21427a90b1030ae38c70ae1faf7/capricor/files/PPMD_2026_HOPE-2_OLE_Late-breaker_6.27.26.pdf)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### HOPE-2 and open-label extension: 36-month external-comparator analysis

> “a modeled yearly decline in PUL 2.0 total score of 3.46 points, compared to a mean decline of 7.19 points in the ECP group”

Source: [McDonald et al. (2025)](https://d1io3yog0oux5.cloudfront.net/_e9bad581d8d3c98ff5505cb2a64c3ec9/capricor/files/pages/our-science/publications/MDA_2025_poster_Final.pdf)

<a id="topic-3.1.3.8.3-2"></a>

###### Three-year modeled change as presented in the five-year update

| Group | Modeled PUL 2.0 change at three years |
| --- | --- |
| Deramiocel | “−3.46” |
| External comparator | “-7.19” |

Source: [Capricor Therapeutics PPMD presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_44a0a21427a90b1030ae38c70ae1faf7/capricor/files/PPMD_2026_HOPE-2_OLE_Late-breaker_6.27.26.pdf)

<a id="topic-3.1.3.8.3-3"></a>

###### HOPE-2 and open-label extension: 36-month PUL v2.0 analysis

| Measure | Reported result |
| --- | --- |
| Deramiocel mean decline | “4.0-pt” |
| External-comparator mean decline | “7.7 points” |
| Difference | “Δ=3.7” |
| Reported p value | “p <0.001” |

Source: [McDonald et al. (2024)](https://d1io3yog0oux5.cloudfront.net/_958553a36c8534969b6e9dd543064101/capricor/files/pages/our-science/publications/WMS_2024_Poster_%28Capricor%29.pdf)

<a id="topic-3.1.3.8.3-4"></a>

###### HOPE-2 open-label extension: five-year upper-limb results

> “HOPE-2 Open-Label Extension (OLE) study”
> “(n=9)”
> “Patients experienced a mean total-score decline of less than 5 points over five years.”

Source: [Capricor Therapeutics PPMD 2026 presentation announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/347/capricor-to-present-positive-five-year-hope-2-ole-data-and)

<a id="topic-3.1.3.8.3-5"></a>

###### Five-year external-comparator projection

> “which if continued would project to approximately 12 points over five years.”

Source: [Capricor Therapeutics PPMD 2026 presentation announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/347/capricor-to-present-positive-five-year-hope-2-ole-data-and)

<a id="topic-3.1.3.8.3-6"></a>

###### Five-year cardiac assessment: number evaluated at month 60

> “N = 10 (7 at Month 60)”

Source: [Capricor Therapeutics PPMD presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_44a0a21427a90b1030ae38c70ae1faf7/capricor/files/PPMD_2026_HOPE-2_OLE_Late-breaker_6.27.26.pdf)

<a id="topic-3.1.3.8.3-7"></a>

###### Five-year cardiac result: sponsor report

> “remained stable over the full five-year period”

Source: [Capricor Therapeutics PPMD 2026 presentation announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/347/capricor-to-present-positive-five-year-hope-2-ole-data-and)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Safety in the 36-month poster

| Measure | Number and percentage |
| --- | --- |
| Participants with any treatment-emergent adverse event | “13 (100.0%)” |
| Participants with a severe treatment-emergent adverse event | “5 (38.5%)” |
| Participants with a treatment-related adverse event | “9 (69.2%)” |
| Participants with a treatment-related serious adverse event | “0” |

Source: [McDonald et al. (2024)](https://d1io3yog0oux5.cloudfront.net/_958553a36c8534969b6e9dd543064101/capricor/files/pages/our-science/publications/WMS_2024_Poster_%28Capricor%29.pdf)

<a id="topic-3.1.3.8.5-2"></a>

###### Treatment-related adverse events in the five-year presentation

> “76.9% any treatment-related TEAE (10 of 13 subjects)”

Source: [Capricor Therapeutics PPMD presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_44a0a21427a90b1030ae38c70ae1faf7/capricor/files/PPMD_2026_HOPE-2_OLE_Late-breaker_6.27.26.pdf)

<a id="topic-3.1.3.8.5-3"></a>

###### Fatal cardiac arrest following a fall: frequency and investigator attribution

> “The single death in the integrated safety database occurred in HOPE-2-OLE (1 of 13 deramiocel-treated patients; 7.7%)”
> “unlikely related to study drug”

Source: [Capricor Therapeutics FDA Advisory Committee briefing document (2026)](https://www.fda.gov/media/193840/download)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

The extension enrolled 13 participants who had completed the parent trial; all received deramiocel, and 9 continued to month 60. The absence of a concurrent randomized control group, selection of prior-trial completers, and attrition limit causal interpretation. External-comparator analyses depend on modeling and cross-study comparability. The five-year comparator estimate is a projection, not an observed five-year randomized comparison. The earlier poster described the 3.46-point and 7.19-point estimates as yearly declines, whereas the later presentation labels them as three-year modeled changes; these descriptions should not be combined as if they used the same time scale. Off-treatment comparisons used linear interpolation, and analyses were exploratory and unadjusted for multiplicity.

Source: [Capricor Therapeutics PPMD presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_44a0a21427a90b1030ae38c70ae1faf7/capricor/files/PPMD_2026_HOPE-2_OLE_Late-breaker_6.27.26.pdf); [University of California, Davis (2025)](https://clinicaltrials.ucdavis.edu/trial/NCT04428476); [McDonald et al. (2025)](https://d1io3yog0oux5.cloudfront.net/_e9bad581d8d3c98ff5505cb2a64c3ec9/capricor/files/pages/our-science/publications/MDA_2025_poster_Final.pdf); [Capricor Therapeutics PPMD 2026 presentation announcement (2026)](https://www.capricor.com/investors/news-events/press-releases/detail/347/capricor-to-present-positive-five-year-hope-2-ole-data-and); [McDonald et al. (2023)](https://d1io3yog0oux5.cloudfront.net/_e7a3fba205f4fce31284150e8f43c824/capricor/files/Long_Term_Safety_and_Efficacy_of_CAP-1002_in_late-stage_patients_with_DMD_Poster.pdf); [Capricor Therapeutics HOPE-2-OLE statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/76/NCT04428476/SAP_001.pdf); [Capricor Therapeutics FDA Advisory Committee briefing document (2026)](https://www.fda.gov/media/193840/download)

<a id="topic-3.1.3.9-2"></a>

###### HOPE-2 open-label extension: statistical qualification

> “comparisons are exploratory and nominal.”

Source: [Capricor Therapeutics FDA Advisory Committee briefing document (2026)](https://www.fda.gov/media/193840/download)

<a id="heading-3.1.4"></a>

#### 3.1.4 HOPE-OLE

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Exploratory safety and efficacy objective

> “explore the safety and efficacy”

Source: [Capricor Therapeutics HOPE-OLE protocol (2018)](https://cdn.clinicaltrials.gov/large-docs/64/NCT06304064/Prot_000.pdf)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Sponsor-reported first-visit and last-visit dates

| Milestone | Reported date |
| --- | --- |
| First participant first visit | “21 Jun 2018” |
| Last participant last visit | “06 Mar 2019” |

Source: [Capricor Therapeutics FDA Advisory Committee briefing document (2026)](https://www.fda.gov/media/193840/download)

<a id="topic-3.1.4.2-2"></a>

###### Planned study centers

> “Up to 3 (USA)”

Source: [Capricor Therapeutics HOPE-OLE protocol (2018)](https://cdn.clinicaltrials.gov/large-docs/64/NCT06304064/Prot_000.pdf)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Open-label extension design

> “Open-labeled extension study”

Source: [Capricor Therapeutics FDA Advisory Committee briefing document (2026)](https://www.fda.gov/media/193840/download)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Prior trial allocation and follow-up

> “Usual Care Treatment Group of the HOPE-Duchenne trial”
> “completed the 12-month follow-up period”

Source: [Capricor Therapeutics HOPE-OLE protocol (2018)](https://cdn.clinicaltrials.gov/large-docs/64/NCT06304064/Prot_000.pdf)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Intravenous dose per administration

> “75M cells”

Source: [Capricor Therapeutics FDA Advisory Committee briefing document (2026)](https://www.fda.gov/media/193840/download)

<a id="topic-3.1.4.5-2"></a>

###### Number of administrations

> “two”

Source: [Capricor Therapeutics Form 10-K (2020)](https://www.sec.gov/Archives/edgar/data/1133869/000110465920039272/tm205377d1_10k.htm)

<a id="topic-3.1.4.5-3"></a>

###### Repeat-dose visit

> “Month 3”

Source: [Capricor Therapeutics HOPE-OLE protocol (2018)](https://cdn.clinicaltrials.gov/large-docs/64/NCT06304064/Prot_000.pdf)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Serious Adverse Events as a Primary Endpoint

Not applicable.

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Planned enrollment

> “10”

Source: [Capricor Therapeutics HOPE-OLE protocol (2018)](https://cdn.clinicaltrials.gov/large-docs/64/NCT06304064/Prot_000.pdf)

<a id="topic-3.1.4.7.1-2"></a>

###### Actual treated population

> “8”

Source: [Capricor Therapeutics FDA Advisory Committee briefing document (2026)](https://www.fda.gov/media/193840/download)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Analysis-set definitions

| Analysis set | Definition excerpt |
| --- | --- |
| Intention to treat | “meet the enrollment criteria and are enrolled in the study” |
| Safety | “all subjects who receive any amount of IP.” |

Source: [Capricor Therapeutics HOPE-OLE statistical analysis plan (2019)](https://cdn.clinicaltrials.gov/large-docs/64/NCT06304064/SAP_001.pdf)

<a id="topic-3.1.4.7.2-2"></a>

###### Descriptive analyses

> “counts and percentages”

Source: [Capricor Therapeutics HOPE-OLE statistical analysis plan (2019)](https://cdn.clinicaltrials.gov/large-docs/64/NCT06304064/SAP_001.pdf)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Completion of enrollment and treatment

> “We have completed enrollment and treatment of the patients in the HOPE-OLE trial.”

Source: [Capricor Therapeutics Form 10-K (2020)](https://www.sec.gov/Archives/edgar/data/1133869/000110465920039272/tm205377d1_10k.htm)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Serious anaphylactic reaction: participants, percentage, and event count

> “1 (12.5), 1”

Source: [Capricor Therapeutics FDA Advisory Committee briefing document (2026)](https://www.fda.gov/media/193840/download)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

HOPE-OLE treated 8 participants who had previously been allocated to usual care in HOPE-Duchenne. It was an open-label extension without a concurrent randomized comparator. The regimen comprised two intravenous administrations of 75 million cells, with the repeat dose at month 3, rather than the 150-million-cell regimen used in HOPE-2 and HOPE-3. The small, selected population and different exposure limit its contribution to efficacy assessment and extrapolation to later dosing regimens.

Source: [Capricor Therapeutics HOPE-OLE protocol (2018)](https://cdn.clinicaltrials.gov/large-docs/64/NCT06304064/Prot_000.pdf); [Capricor Therapeutics FDA Advisory Committee briefing document (2026)](https://www.fda.gov/media/193840/download); [Capricor Therapeutics Form 10-K (2020)](https://www.sec.gov/Archives/edgar/data/1133869/000110465920039272/tm205377d1_10k.htm); [Capricor Therapeutics HOPE-2 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/80/NCT03406780/Prot_001.pdf); [Capricor Therapeutics HOPE-3 topline results announcement (2025)](https://www.capricor.com/investors/news-events/press-releases/detail/331/capricor-therapeutics-announces-positive-topline-results)

<a id="heading-3.1.5"></a>

#### 3.1.5 HOPE-Duchenne

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Safety and efficacy objective

> “evaluated the safety and efficacy”

Source: [Capricor Therapeutics HOPE publication announcement (2019)](https://www.capricor.com/investors/news-events/press-releases/detail/91/neurology-publishes-study-reporting-significant)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### HOPE-Duchenne: location

> “three centers in the U.S.”

Source: [Capricor Therapeutics HOPE publication announcement (2019)](https://www.capricor.com/investors/news-events/press-releases/detail/91/neurology-publishes-study-reporting-significant)

<a id="topic-3.1.5.2-2"></a>

###### Enrollment period

| Milestone | Reported date |
| --- | --- |
| Enrollment began | “January 7, 2016” |
| Enrollment ended | “August 15, 2016” |

Source: [Taylor et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6396968/)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Early randomized controlled design

> “Phase I/II, randomized, controlled, open-label trial”

Source: [Capricor Therapeutics HOPE publication announcement (2019)](https://www.capricor.com/investors/news-events/press-releases/detail/91/neurology-publishes-study-reporting-significant)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Cardiac disease in the studied population

> “significant cardiac scarring”

Source: [Capricor Therapeutics HOPE publication announcement (2019)](https://www.capricor.com/investors/news-events/press-releases/detail/91/neurology-publishes-study-reporting-significant)

<a id="topic-3.1.5.4-2"></a>

###### Minimum age in the sponsor study summary

> “12”

Source: [Capricor Therapeutics FDA Advisory Committee briefing document (2026)](https://www.fda.gov/media/193840/download)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### HOPE-Duchenne: intracoronary administration

> “13 also received one dose of intracoronary CAP-1002 (75 million cells)”

Source: [Capricor Therapeutics HOPE publication announcement (2019)](https://www.capricor.com/investors/news-events/press-releases/detail/91/neurology-publishes-study-reporting-significant)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Serious Adverse Events as the Primary Endpoint

Not applicable.

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### HOPE-Duchenne: actual enrollment

> “The HOPE-Duchenne clinical trial enrolled 25 patients”

Source: [Capricor Therapeutics HOPE publication announcement (2019)](https://www.capricor.com/investors/news-events/press-releases/detail/91/neurology-publishes-study-reporting-significant)

<a id="topic-3.1.5.7.1-2"></a>

###### Target sample size

> “24–30”

Source: [Taylor et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6396968/)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Primary efficacy analysis population

> “modified intent to treat”

Source: [Taylor et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6396968/)

<a id="topic-3.1.5.7.2-2"></a>

###### HOPE-Duchenne: upper-limb analysis qualification

> “responder analyses”
> “post hoc”

Source: [Taylor et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6396968/)

<a id="topic-3.1.5.7.2-3"></a>

###### Multiplicity

> “with no adjustments for multiplicity.”

Source: [Taylor et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6396968/)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Discontinuation due to adverse events

> “no early study discontinuations due to adverse events.”

Source: [Capricor Therapeutics Form 10-K (2020)](https://www.sec.gov/Archives/edgar/data/1133869/000110465920039272/tm205377d1_10k.htm)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Wheelchair dependence

> “approximately two-thirds were wheelchair-dependent”

Source: [Capricor Therapeutics HOPE publication announcement (2019)](https://www.capricor.com/investors/news-events/press-releases/detail/91/neurology-publishes-study-reporting-significant)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### HOPE-Duchenne: upper-limb findings

> “Mid-distal PUL improved at 12 months in 8 of 9 lower functioning CAP-1002 patients, and no controls (p = 0.007).”

Source: [Taylor et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6396968/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

###### Exploratory questionnaire findings: nominal comparisons favouring CAP-1002 unless stated otherwise

| Instrument and comparison | Reported p value |
| --- | --- |
| Pediatric Outcomes Data Collection Instrument: patient-reported global function, month 3 | “0.02” |
| Pediatric Outcomes Data Collection Instrument: patient-reported happiness, month 12 | “0.03” |
| Pediatric Outcomes Data Collection Instrument: parent-reported happiness, month 12 | “0.0003” |
| Pediatric Quality of Life Inventory: patient-reported worry, month 6 | “0.047” |
| Pediatric Quality of Life Inventory: patient-reported worry, month 12 | “0.043” |
| Pediatric Quality of Life Inventory: patient-reported communication, month 6 | “0.043” |
| Pediatric Quality of Life Inventory: patient-reported communication, month 12 | “0.01” |
| Pediatric Quality of Life Inventory: treatment barriers, week 6, favouring usual care | “0.01” |

Source: [Taylor et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6396968/)

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Periprocedural major adverse cardiac events in each group

> “0”

Source: [Taylor et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6396968/)

<a id="topic-3.1.5.8.5-2"></a>

###### Sponsor safety overview

> “no serious safety issues”

Source: [Capricor Therapeutics HOPE publication announcement (2019)](https://www.capricor.com/investors/news-events/press-releases/detail/91/neurology-publishes-study-reporting-significant)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

HOPE-Duchenne was an open-label phase I/II trial with 25 participants and a single intracoronary administration rather than the repeated intravenous regimen used in later trials. The upper-limb responder analysis and definition of the lower-functioning subgroup were post hoc. Statistical testing did not adjust for multiplicity, so the nominal questionnaire and functional findings should not be interpreted as independently confirmed effects. Its size, open-label design, and different route and dosing schedule limit extrapolation to the proposed repeated-infusion treatment.

Source: [Capricor Therapeutics HOPE publication announcement (2019)](https://www.capricor.com/investors/news-events/press-releases/detail/91/neurology-publishes-study-reporting-significant); [Taylor et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6396968/); [Capricor Therapeutics HOPE-2 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/80/NCT03406780/Prot_001.pdf)

## Related pages
- [Deramiocel (CAP-1002): Duchenne muscular dystrophy](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy.md)
- [Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Terms and abbreviations](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/terms-and-abbreviations.md)
- [Deramiocel (CAP-1002): Duchenne muscular dystrophy](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/executive-summary.md)
- [Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Product information and disease description](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/product-information-and-disease-description.md)
- [Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Economic information and modeling report](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/economics) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/economics.md)
- [Deramiocel (CAP-1002) in Duchenne muscular dystrophy: References](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/references) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/references.md)
- [Deramiocel (CAP-1002) in Duchenne muscular dystrophy: prevalence by geography](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/prevalence) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/prevalence.md)
- [Deramiocel (CAP-1002) in Duchenne muscular dystrophy: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/cost-effectiveness-analyses.md)
